Essential Thrombocythemia — Trials

Essential Thrombocythemia — Trials · CancerIndex

Clinical trials

Registered studies

93 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 24
Recruiting: 15
Ph III recruiting: 2
Growth YoY: —
Industry share: 25%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (6)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03878199	Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms	terminated	Phase 1 / Phase 2	12	Ohio State University Comprehensive Cancer CenterOTHER	1	Apr 24, 2026	clinicaltrials
NCT01014546	Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis	terminated	Phase 1	5	Roswell Park Cancer InstituteOTHER	1	Jul 22, 2022